Literature DB >> 31447342

[Reirradiation of brain metastasis: Review of the last five years].

M-N Nguyen1, G Noel2, D Antoni3.   

Abstract

No recommandations have been established for reirradiation of brain metastases yet. The purpose of this review is to analyse the data of the five last years about the feasibility, efficacy and tolerance of reirradiation of brain metastases. Reirradiation can be 3D conformal or stereotactic. Whole brain irradiation seems appropriate for multiple brain metastases in order to obtain symptomatic relief, with or without supportive care. Stereotactic reirradiation has shown satisfying results in terms of overall survival, local control, without significant toxicity. Prospective trials are necessary in order to validate consensual recommandations.
Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Brain metastases; Irradiation de l’encéphale en totalité; Métastases cérébrales; Radiothérapie en conditions stéréotaxiques; Reirradiation; Stereotactic radiotherapy; Whole brain radiotherapy

Mesh:

Year:  2019        PMID: 31447342     DOI: 10.1016/j.canrad.2019.07.144

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Local recurrence and cerebral progression-free survival after multiple sessions of stereotactic radiotherapy of brain metastases: a retrospective study of 184 patients : Statistical analysis.

Authors:  Laure Kuntz; Clara Le Fèvre; Delphine Jarnet; Audrey Keller; Philippe Meyer; Caroline Bund; Isabelle Chambrelant; Delphine Antoni; Georges Noel
Journal:  Strahlenther Onkol       Date:  2022-03-16       Impact factor: 4.033

2.  Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population.

Authors:  K Holub; G Louvel
Journal:  Clin Transl Oncol       Date:  2021-01-19       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.